Unassociated Document
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)
October 30, 2007

 
NEOPROBE CORPORATION
(Exact name of registrant as specified in its charter)

Delaware
0-26520
31-1080091
(State or other jurisdiction
(Commission
(IRS Employer
of incorporation)
File Number)
Identification No.)

425 Metro Place North, Suite 300, Columbus, Ohio
43017
(Address of principal executive offices)
(Zip Code)

Registrant's telephone number, including area code
(614) 793-7500
 
    
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
Item 2.02.   Results of Operations and Financial Condition.
 
On October 30, 2007, Neoprobe Corporation (the “Company”) issued a press release regarding its consolidated financial results for the third quarter ended September 30, 2007. A copy of the Company’s October 30, 2007, press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in Item 2.02 of this Current Report on Form 8-K, including exhibit 99.1 hereto, shall not be treated as “filed” for purposes of the Securities Exchange Act of 1934, as amended.
 
Item 8.01.   Other Events.
 
On October 30, 2007, the Company also issued a press release announcing that the Company held an end of Phase 2 meeting with the U.S. Food and Drug Administration (the “FDA”) to review the conduct of a successfully completed multicenter Phase 2 study of Lymphoseek. In addition, the Company and the FDA reviewed proposed protocols for Phase 3 clinical studies of Lymphoseek. At the conclusion of the discussion, the Company and the FDA were in concurrence regarding the design of the Phase 3 studies. A copy of the complete text of the Company’s October 30, 2007, press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.
 
Statements contained or incorporated by reference in this Current Report on Form 8-K which relate to other than strictly historical facts, such as statements about the Company’s plans and strategies, expectations for future financial performance, new and existing products and technologies, and markets for the Company’s products, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company’s continuing operating losses, uncertainty of market acceptance, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, and other risks detailed in the Company’s most recent Annual Report on Form 10-KSB and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.
 
Item 9.01 Financial Statements and Exhibits.
 
(d) Exhibits.
 
Exhibit Number
Exhibit Description
   
99.1
Neoprobe Corporation press release dated October 30, 2007, entitled “Neoprobe Announces Third Quarter Results.”
   
99.2
Neoprobe Corporation press release dated October 30, 2007, entitled “Neoprobe Completes FDA Meeting Regarding Lymphoseek.”
 
2
SIGNATURES

 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

 
Neoprobe Corporation
 
 
 
 
 
 
Date: October 30, 2007
By:
/s/ Brent L. Larson   
 
 
Brent L. Larson, Vice President, Finance and
  Chief Financial Officer
 

 
3